EGFR and non-small cell lung carcinoma: The coexistence of activating EGFR mutation and pretreatment T790M mutation has been underestimated, despite accumulating evidence that the pretreatment T790M mutation occurs in approximately 35–60% of patients with EGFR-mutant NSCLC, depending on the detection method [31].